These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 23790235

  • 1. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
    Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, DeGryse RE, Turkel CC, Dodick DW.
    J Neurol Sci; 2013 Aug 15; 331(1-2):48-56. PubMed ID: 23790235
    [Abstract] [Full Text] [Related]

  • 2. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
    Aurora SK, Winner P, Freeman MC, Spierings EL, Heiring JO, DeGryse RE, VanDenburgh AM, Nolan ME, Turkel CC.
    Headache; 2011 Oct 15; 51(9):1358-73. PubMed ID: 21883197
    [Abstract] [Full Text] [Related]

  • 3. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
    Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT Chronic Migraine Study Group.
    Headache; 2010 Jun 15; 50(6):921-36. PubMed ID: 20487038
    [Abstract] [Full Text] [Related]

  • 4. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
    Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 15; 30(7):793-803. PubMed ID: 20647170
    [Abstract] [Full Text] [Related]

  • 5. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R, Schreiber C.
    Headache; 2008 Jun 15; 48(6):900-13. PubMed ID: 18047501
    [Abstract] [Full Text] [Related]

  • 6. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine.
    Lipton RB, Varon SF, Grosberg B, McAllister PJ, Freitag F, Aurora SK, Dodick DW, Silberstein SD, Diener HC, DeGryse RE, Nolan ME, Turkel CC.
    Neurology; 2011 Oct 11; 77(15):1465-72. PubMed ID: 21956721
    [Abstract] [Full Text] [Related]

  • 7. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.
    Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD.
    Acta Neurol Scand; 2014 Jan 11; 129(1):61-70. PubMed ID: 24107267
    [Abstract] [Full Text] [Related]

  • 8. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
    Aurora SK, Gawel M, Brandes JL, Pokta S, Vandenburgh AM, BOTOX North American Episodic Migraine Study Group.
    Headache; 2007 Apr 11; 47(4):486-99. PubMed ID: 17445098
    [Abstract] [Full Text] [Related]

  • 9. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK, Sadowsky CH, Martinez WC, Zuniga JA, Poulette A.
    Headache; 2012 Sep 11; 52(8):1219-25. PubMed ID: 22607530
    [Abstract] [Full Text] [Related]

  • 10. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
    Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU.
    Headache; 2011 Jan 11; 51(1):21-32. PubMed ID: 21070228
    [Abstract] [Full Text] [Related]

  • 11. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.
    Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group.
    Cephalalgia; 2010 Jul 11; 30(7):804-14. PubMed ID: 20647171
    [Abstract] [Full Text] [Related]

  • 12. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
    Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, TOPMAT-MIG-201(TOP-CHROME) Study Group.
    Cephalalgia; 2007 Jul 11; 27(7):814-23. PubMed ID: 17441971
    [Abstract] [Full Text] [Related]

  • 13. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD, BOTOX CDH Study Group.
    Headache; 2005 Apr 11; 45(4):315-24. PubMed ID: 15836567
    [Abstract] [Full Text] [Related]

  • 14. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
    Young WB, Ivan Lopez J, Rothrock JF, Orejudos A, Manack Adams A, Lipton RB, Blumenfeld AM.
    J Headache Pain; 2019 Feb 01; 20(1):12. PubMed ID: 30709333
    [Abstract] [Full Text] [Related]

  • 15. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC.
    J Neurol Neurosurg Psychiatry; 2015 Sep 01; 86(9):996-1001. PubMed ID: 25500317
    [Abstract] [Full Text] [Related]

  • 16. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
    Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB.
    Headache; 2024 Sep 01; 64(7):838-848. PubMed ID: 38982666
    [Abstract] [Full Text] [Related]

  • 17. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse.
    Freitag FG, Diamond S, Diamond M, Urban G.
    Headache; 2008 Feb 01; 48(2):201-9. PubMed ID: 18042229
    [Abstract] [Full Text] [Related]

  • 18. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
    Frampton JE.
    Drugs; 2012 Apr 16; 72(6):825-45. PubMed ID: 22468643
    [Abstract] [Full Text] [Related]

  • 19. [Botulinum toxin type A (Relatox) in transition from medication overuse to non-overuse status in patients with chronic migraine: a subgroup analysis of phase IIIb randomized single-blind multicenter active-controlled parallel-group trial].
    Artemenko AR, Abramov VG, Bozhenkina TV, Konovalova ZN, Korenko AN, Krasavina DA, Kurenkov AL, Latysheva NV, Naprienko MV, Orlova OR, Filatova EG, Shevchenko VS, Iakovleva PN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023 Apr 16; 123(11):64-74. PubMed ID: 37994890
    [Abstract] [Full Text] [Related]

  • 20. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD.
    J Pain; 2015 Feb 16; 16(2):164-75. PubMed ID: 25464159
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.